
Mevidalen Misses Primary Endpoint in Phase 2 Alzheimer Trial
Key Takeaways
- PRESENCE-ALZ randomized 304 adults (US/Japan) with MMSE 13–24 and AD pathology evidence to placebo or mevidalen 25/50 mg daily for 24 weeks, with discontinuation for vital-sign changes.
- Bayesian primary analysis missed efficacy: posterior probabilities for ≥2-point iADRS benefit were 14.0% (25 mg) and 21.2% (50 mg), with LS mean differences <1 point.
Results from Eli Lilly's phase 2 PRESENCE-ALZ trial show the dopamine D1 receptor modulator missed its primary cognitive and functional goal in Alzheimer disease.
Eli Lilly's mevidalen, an investigational dopamine D1 receptor (D1R) positive allosteric modulator, failed to improve cognition and daily function enough to clear the primary efficacy bar in PRESENCE-ALZ, a phase 2 trial of people with mild-to-moderate Alzheimer disease (AD). The company presented full results as a poster at the
PRESENCE-ALZ (NCT06538116), led by Adam S. Fleisher, MD, PhD, of Eli Lilly, randomized 304 adults in the US and Japan, 1:1:1, to placebo, mevidalen 25 mg, or mevidalen 50 mg once daily for 24 weeks, with doses permanently discontinued during an initial titration period for participants who had potentially clinically significant pre- or post-dose changes in blood pressure or pulse. Eligible participants were 50 to 80 years old, had evidence of AD pathology by plasma p-tau217 testing or prior biomarker history, a gradual decline of 6 months or longer affecting daily activities, and a Mini-Mental State Examination (MMSE) score of 13 to 24.
The primary endpoint was change from baseline to week 24 on the Integrated Alzheimer's Disease Rating Scale (iADRS), analyzed with a Bayesian model requiring a greater than 60% posterior probability that either dose would produce at least a 2-point benefit over placebo. The posterior probabilities were 14.0% for mevidalen 25 mg and 21.2% for mevidalen 50 mg, well short of that threshold. Least-squares mean differences versus placebo were 0.62 points (95% CI, -2.27 to 3.50) with 25 mg and 0.95 points (95% CI, -1.95 to 3.86) with 50 mg.
Among the secondary and exploratory endpoints, which spanned cognitive tests (the Alzheimer's Disease Assessment Scale-Cognitive Subscale, verbal and category fluency, digit symbol coding, and MMSE), function and global measures (the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale, the Quick Dementia Rating System [QDRS], and clinician-rated global impression of change), a neuropsychiatric inventory, and a sleepiness scale, only the QDRS showed a nominally significant difference, favoring mevidalen 50 mg over placebo by 1.04 points (95% CI, 0.13-1.95; nominal P = .025).
Treatment-emergent adverse events (TEAEs) occurred at comparable rates across arms, in 65.7% of patients on placebo, 65.1% on mevidalen 25 mg, and 62.5% on mevidalen 50 mg; serious adverse events (SAEs) occurred in 5.9%, 9.4%, and 5.2%, respectively, and no deaths or major adverse cardiovascular events were reported. The most common TEAEs involved infections, laboratory abnormalities, and gastrointestinal disorders. In both mevidalen arms, systolic blood pressure rose by roughly 8 to 11 mm Hg relative to pre-dose levels during the 4-hour monitoring window at each titration visit.1
READ MORE:
Mevidalen amplifies the effect of endogenous dopamine at D1R, a receptor whose expression is reduced in the prefrontal cortex of people with AD, without the overstimulation or tolerance that can limit direct D1R agonists.
The approach had already been tested once before: in a phase 2 trial in people with Lewy body dementia (LBD), also called PRESENCE, mevidalen missed its primary cognitive endpoint but showed signals of benefit on global impression of change, motor symptoms, and daytime sleepiness, mainly at a 75-mg dose that was later dropped from that study after 4 serious cardiovascular events; blood pressure increases at that higher dose also persisted over time.2
PRESENCE-ALZ extended the same mechanism to a different population without replicating even those modest secondary signals on most measures. Eli Lilly concluded that the trial “did not provide evidence supporting significant clinical benefit of D1-mediated dopamine potentiation” in people with mild-to-moderate AD, while noting mevidalen's acceptable safety profile across both the Alzheimer and Lewy body dementia programs.1,2
For more CTAD 2026 coverage,
REFERENCES
1. Fleisher AS, Mehdiyoun NF, Hu H, Tronchin G, Hansson O. Safety and efficacy of mevidalen in Alzheimer's disease: a phase 2, randomized, double-blinded trial. Presented at: 2026 Clinical Trials on Alzheimer's Disease Conference; November 16-19, 2026; Boston, MA. Poster P-029.
2. Biglan K, Munsie L, Svensson KA, et al. Safety and efficacy of mevidalen in Lewy body dementia: a phase 2, randomized, placebo-controlled trial. Mov Disord. 2022;37(3):513-524. doi:10.1002/mds.28879
Related to this article








